Trial Profile
Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Umbralisib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Nov 2020 Status changed from recruiting to discontinued.
- 24 Jul 2019 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
- 24 Jul 2019 Planned primary completion date changed from 1 Aug 2018 to 1 Oct 2019.